TY - JOUR
T1 - High-Density EEG in Current Clinical Practice and Opportunities for the Future
AU - Stoyell, Sally M.
AU - Wilmskoetter, Janina
AU - Dobrota, Mary Ann
AU - Chinappen, Dhinakaran M.
AU - Bonilha, Leonardo
AU - Mintz, Mark
AU - Brinkmann, Benjamin H.
AU - Herman, Susan T.
AU - Peters, Jurriaan M.
AU - Vulliemoz, Serge
AU - Seeck, Margitta
AU - Hämäläinen, Matti S.
AU - Chu, Catherine J.
N1 - Funding Information:
C. J. Chu is supported by NIH NINDS K23-NS092923 and NINDS R01NS119483 and consults for Biogen, Inc and SleepMed, Inc. L. Bonilha’s research laboratory receives support from Medtronic. S. Vulliemoz is supported by SNSF CRSII5_170873 and 192749. M. Seeck is supported by 163398 and CRS115-180365. M. Seeck and S. Vulliemoz are advisors and shareholders of Epilog NV (Ghent, Belgium). J. Peters consults for Philips Neuro. B. Brinkmann received nonfinancial research support from Medtronic and has licensed IP to Cadence Neurosciences. M. Hämäläinen is supported by NIH NIBIB 5U01EB023820 S.T. Herman sits on a Neuropace Advisory Committee meeting and her institution has received research support from UCB Pharma. M. Mintz serves on the editorial boards of the Journal of Child Neurology and Vision Development and Rehabilitation; has functioned as principal investigator for clinical trials research, contracted through the Clinical Research Center of New Jersey (CRCNJ), and sponsored by the following companies: Aquestive Therapeutics, Curemark, Eisai Inc., Impax Laboratories, Neurim Pharmaceuticals, Nuvelution Pharma Inc., PhenoSolve, Sunovion, and Teva. M. Mintz has been a consultant to Philips-Electrical Geodesics contracted through The Center for Neurological and Neurodevelopmental Health (CNNH NeuroHealth, dba NeurAbilities Healthcare); and is on the scientific advisory board of NeuroNeeds. M. Mintz is Chief Medical Officer, Owner and Founder of NeurAbilities Healthcare, CNNH NeuroHealth and CRCNJ; Board Member of CNNH Management, Inc.; and is President and Founder of CNNH-II, a 501(3)c public charity. M. Mintz has functioned as an expert witness in various litigation and mitigation cases, contracted through CNNH NeuroHealth. The remaining authors have no funding or conflicts of interest to disclose.
Funding Information:
C. J. Chu is supported by NIH NINDS K23-NS092923 and NINDS R01NS119483 and consults for Biogen, Inc and SleepMed, Inc. L. Bonilha's research laboratory receives support from Medtronic. S. Vulliemoz is supported by SNSF CRSII5-170873 and 192749. M. Seeck is supported by 163398 and CRS115-180365. M. Seeck and S. Vulliemoz are advisors and shareholders of Epilog NV (Ghent, Belgium). J. Peters consults for Philips Neuro. B. Brinkmann received nonfinancial research support from Medtronic and has licensed IP to Cadence Neurosciences. M. Hämäläinen is supported by NIH NIBIB 5U01EB023820 S.T.
Publisher Copyright:
Copyright © 2021 by the American Clinical Neurophysiology Society.
PY - 2021
Y1 - 2021
N2 - High-density EEG (HD-EEG) recordings use a higher spatial sampling of scalp electrodes than a standard 10-20 lowdensity EEG montage. Although several studies have demonstrated improved localization of the epileptogenic cortex using HD-EEG, widespread implementation is impeded by cost, setup and interpretation time, and lack of specific or sufficient procedural billing codes. Despite these barriers, HD-EEG has been in use at several institutions for years. These centers have noted utility in a variety of clinical scenarios where increased spatial resolution from HD-EEG has been required, justifying the extra time and cost. We share select scenarios from several centers, using different recording techniques and software, where HD-EEG provided information above and beyond the standard low-density EEG. We include seven cases where HD-EEG contributed directly to current clinical care of epilepsy patients and highlight two novel techniques which suggest potential opportunities to improve future clinical care. Cases illustrate how HD-EEG allows clinicians to: case 1dlateralize falsely generalized interictal epileptiform discharges; case 2dimprove localization of falsely generalized epileptic spasms; cases 3 and 4dimprove localization of interictal epileptiform discharges in anatomic regions below the circumferential limit of standard lowdensity EEG coverage; case 5dimprove noninvasive localization of the seizure onset zone in lesional epilepsy; cases 6 and 7dimprove localization of the seizure onset zone to guide invasive investigation near eloquent cortex; case 8didentify epileptic fast oscillations; and case 9dmap language cortex. Together, these nine cases illustrate that using both visual analysis and advanced techniques, HD-EEG can play an important role in clinical management.
AB - High-density EEG (HD-EEG) recordings use a higher spatial sampling of scalp electrodes than a standard 10-20 lowdensity EEG montage. Although several studies have demonstrated improved localization of the epileptogenic cortex using HD-EEG, widespread implementation is impeded by cost, setup and interpretation time, and lack of specific or sufficient procedural billing codes. Despite these barriers, HD-EEG has been in use at several institutions for years. These centers have noted utility in a variety of clinical scenarios where increased spatial resolution from HD-EEG has been required, justifying the extra time and cost. We share select scenarios from several centers, using different recording techniques and software, where HD-EEG provided information above and beyond the standard low-density EEG. We include seven cases where HD-EEG contributed directly to current clinical care of epilepsy patients and highlight two novel techniques which suggest potential opportunities to improve future clinical care. Cases illustrate how HD-EEG allows clinicians to: case 1dlateralize falsely generalized interictal epileptiform discharges; case 2dimprove localization of falsely generalized epileptic spasms; cases 3 and 4dimprove localization of interictal epileptiform discharges in anatomic regions below the circumferential limit of standard lowdensity EEG coverage; case 5dimprove noninvasive localization of the seizure onset zone in lesional epilepsy; cases 6 and 7dimprove localization of the seizure onset zone to guide invasive investigation near eloquent cortex; case 8didentify epileptic fast oscillations; and case 9dmap language cortex. Together, these nine cases illustrate that using both visual analysis and advanced techniques, HD-EEG can play an important role in clinical management.
KW - Electrical source imaging
KW - Epilepsy
KW - HD-EEG
KW - Localization
KW - Noninvasive
KW - Spatial resolution
UR - http://www.scopus.com/inward/record.url?scp=85102685531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102685531&partnerID=8YFLogxK
U2 - 10.1097/WNP.0000000000000807
DO - 10.1097/WNP.0000000000000807
M3 - Article
C2 - 33661787
AN - SCOPUS:85102685531
SN - 0736-0258
VL - 38
SP - 112
EP - 123
JO - Journal of Clinical Neurophysiology
JF - Journal of Clinical Neurophysiology
IS - 2
ER -